Scott, T. A. et al. (2017) Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell, 169(3), 442-456.e18. (doi: 10.1016/j.cell.2017.03.040) (PMID:28431245) (PMCID:PMC5406385) Full text not currently available from Enlighten. Abstract Fluoropyrimidines are the first-line treatment for colorectal cancer, but their efficacy is highly variable between patients. We queried whether gut microbes, a known source of inter-individual variability, impacted drug efficacy.